BioPharma Resources

Investigational drug · Phase 3

Favezelimab

Also called: MK-4280, MK-4820A

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Carcinoma, Renal Cell, Solid Tumors.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

2 still active

All registered trials

18

Any phase or sponsor naming "Favezelimab"

First trial start

2018

Aug 21, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Favezelimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Melanoma
  • Carcinoma, Renal Cell
  • Solid Tumors
  • Hematologic Malignancies
  • Metastatic Urothelial Carcinoma
  • Urothelial Neoplasms
  • Solid Tumor
  • Cutaneous Squamous Cell Carcinoma
  • Endometrial Cancer
  • Hodgkin Lymphoma

Approved drugs for the same conditions: Melanoma · Bladder and urothelial cancer · Endometrial cancer · Hodgkin lymphoma · Oncology · Hematology and blood cancers · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Favezelimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 12 on PubMed

Also in development for Melanoma

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • IBI363Phase 37 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer

  • OH2Phase 36 trials

    Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer

  • PucotenlimabHX008Phase 36 trials

    Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma

  • CeralasertibAZD6738Phase 35 trials

    AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.